Healthcare giant Johnson & Johnson to split into two companies
The world's largest health-products company by sales revealed earlier today that it plans to split the consumer health division from the pharmaceuticals unit. After the split, the consumer health business will become a new publicly traded company.
Joaquin Duato, J&J's CEO starting January 2022, stated: "The new Johnson & Johnson and the New Consumer Health Company would each be able to more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value."
Despite the split, the company plans to keep its total dividend "at least at the same level" – 2.6%.
The business separation is expected to be complete in 18 to 24 months. J&J will keep the pharmaceuticals and medical device units, expected to generate roughly $77 billion in revenue in 2021.
J&J is the second US company this week that announces a split, after General Electric. After the news hit the wires, Johnson & Johnson stock price added 4% before the opening bell.
Sources: reuters.com, wsj.com
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.